Biogen (BIIB) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic focus and operational changes

• Leadership and board changes have led to a renewed focus on shareholder returns and cost management.

• Efforts are underway to halt revenue decline, flatten performance, and implement a cost savings program.

• Pipeline strategy now balances high-risk innovation with more traditional, lower-risk programs supported by proof-of-concept data.

• Portfolio refresh includes recent acquisitions and a focus on profitable, sustainable growth.

• Internal alignment and culture shift emphasize value creation for both patients and shareholders.

Leqembi launch and market development

• Initial expectations for Leqembi sales were reset due to the need to build dementia care infrastructure and market awareness.

• Growth is gradual, with unaffiliated practices adopting faster than integrated delivery networks, but the latter are expected to drive future momentum.

• Physician experience and patient outcomes are building confidence, with no centers reversing course after adoption.

• Subcutaneous (sub-Q) formulations are in development, with maintenance filing expected by October and induction filing targeted for early next year.

• Blood-based biomarkers and easier administration are anticipated to further support adoption.

Competitive landscape and regulatory updates

• Kisunla (donanemab) from Lilly has entered the market, but Leqembi maintains a lead; the market is expected to support multiple entrants.

• Recent negative CHMP opinion in Europe has triggered a reexamination process, with a decision expected in fiscal Q4.

• The company is seeking to include new long-term data in the European review, aiming to address benefit-risk concerns.

• If the reexamination is unsuccessful, a new application process may be required.

• Investors will be promptly informed of regulatory outcomes via press release.